New combo therapy aims to halt spread of prostate cancer
NCT ID NCT04748042
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 study tests a combination of radiation, hormone therapy (ADT), and two drugs (abiraterone and olaparib) in 21 men with prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can prevent the cancer from growing or spreading further. Participants receive treatment for about 6 months and are followed for 24 months to check for treatment failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abiraterone, Olaparib, Androgen Deprivation Therapy (ADT), and radiation therapy
What this could lead to
If successful, this combination could offer a new way to control prostate cancer that has spread to a few areas, potentially delaying further progression.
What could go wrong
This is a small, early-phase study with only 21 participants, so results may not apply to everyone. The treatment combines multiple drugs with side effects, and it is not yet known if it works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States